Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

Alexander Tenenbaum, Enrique Z. Fisman, Valentina Boyko, Michal Benderly, David Tanne, Moti Haim, Zipora Matas, Michael Motro, Solomon Behar

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Development of insulin resistance (IR) may be important in the pathogenesis of both metabolic syndrome and type 2 diabetes mellitus. Few data are available regarding the short-term efficacy of the peroxisome proliferator-activated receptor ligand bezafibrate on IR, and its long-term effect is unknown. The present analysis aimed to investigate the effect of bezafibrate on IR in patients with coronary artery disease enrolled in the Bezafibrate Infarction Prevention Study. Methods: Metabolic and inflammatory parameters were analyzed from stored frozen plasma samples obtained from patients who completed a 2-year, randomized, double-blind, placebo-controlled study. The homeostatic indexes of IR (HOMA-IRs) were calculated according to the homeostasis model of assessment. Results: Both the patients taking bezafibrate (n = 1262) and those taking placebo (n = 1242) displayed similar baseline characteristics. The HOMA-IRs significantly correlated at baseline and during follow-up with glucose (r=0.35 and 0.31, respectively) and triglycerides (r=0.16 and 0.19, respectively). In a subgroup of 351 patients with diabetes, HOMA-IR at baseline was 88% higher than in their counterparts with normal glucose levels (P<.001). In the placebo group, during follow-up there was a significant 34.4% rise in HOMA-IR. In contrast, in the bezafibrate group there was only a nonsignificant 6.6% change in HOMA-IR. The intergroup differences in percentage changes of HOMA-IR were in favor of bezafibrate (P<.001). Conclusions: In patients with coronary artery disease enrolled in our study, as represented by the placebo group, HOMA-IR increased over time. During the 2 years of the follow-up, bezafibrate significantly attenuated this process.

Original languageEnglish
Pages (from-to)737-741
Number of pages5
JournalArchives of Internal Medicine
Volume166
Issue number7
DOIs
StatePublished - 10 Apr 2006
Externally publishedYes

Fingerprint

Dive into the research topics of 'Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate'. Together they form a unique fingerprint.

Cite this